CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study
A. Belogurov Jr., K. Zakharov, Y. Lomakin, K. Surkov, S. Avtushenko, P. Kruglyakov, I. Smirnov, G. Makshakov, C. Lockshin, G. Gregoriadis, D. Genkin, A. Gabibov, E. Evdoshenko · 2016 · Neurotherapeutics. 2016;13:895–904
Reported findings and study design
Uncontrolled Phase I study; 20 MS patients enrolled at four Russian centers.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| EDSS and MRI at study exit | No statistically significant change versus baseline | |
| Active gadolinium-enhancing lesions | Transient increase at weeks 7 and 10 |
Small open-label study cannot establish clinical efficacy, restored tolerance or long-term safety. Early MRI activity remains relevant despite unchanged exit measures.
Source for the extracted data ↗ · Checked 2026-11-05
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Uncontrolled safety and proof-of-concept study; not evidence of reduced relapses or disability progression.
- Early MRI activity must be considered alongside the authors’ tolerability findings.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Related-report group: xemys-fasems-2013-2014. Reports in this group are not assumed to be independent trials.
Source access and review scope
Primary publication checked for Phase I design and clinical/MRI outcomes.
Recorded source-check date: 2026-11-05. This date does not imply a completed systematic review.
Citation and original source
Original source: A. Belogurov Jr., K. Zakharov, Y. Lomakin, K. Surkov, S. Avtushenko, P. Kruglyakov, I. Smirnov, G. Makshakov, C. Lockshin, G. Gregoriadis, D. Genkin, A. Gabibov, E. Evdoshenko. CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study Neurotherapeutics. 2016;13:895–904 2016.
Molekul research summary: https://molekul.io/research/auto-xemys-phase1-2016. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry